Mogroside V

Mogroside V
Product Name Mogroside V
CAS No.: 88901-36-4
Catalog No.: CFN99937
Molecular Formula: C60H102O29
Molecular Weight: 1287.44 g/mol
Purity: >=98%
Type of Compound: Triterpenoids
Physical Desc.: Powder
Targets: AMPK | Immunology & Inflammation related
Source: The fruits of Siraitia grosvenorii Swingle.
Solvent: DMSO, Pyridine, Methanol, Ethanol, etc.
Price: $40/20mg
Mogroside V is a widely used sweetener, has in vitro AMPK activating effect, it also has anti-inflammatory potential in murine macrophages and a murine ear edema model, and has the potential to protect against LPS-induced airway inflammation in a model of ALI.
Inquire / Order: manager@chemfaces.com
Technical Inquiries: service@chemfaces.com
Tel: +86-27-84237783
Fax: +86-27-84254680

Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
  • Front Aging Neurosci.2018, 10:269
  • Korean J of Pharmacognosy2020, 51,49-54.
  • Biomimetics (Basel).2022, 7(4):154.
  • Int J Biol Macromol.2020, 169:342-351
  • Toxicol Res.2019, 35(4):371-387
  • Pharmacol Rep.2018, 70(6):1195-1201
  • Journal of Functional Foods2022, 91:105019.
  • Appl. Sci.2020, 10,1304
  • Advances in Traditional Medicine 2021, 21:779-789.
  • Molecules.2023, 28(7):3039.
  • 11-Oxomogroside IIA2

    Catalog No: CFN95305
    CAS No: 2170761-37-0
    Price: $368/5mg
    Mogroside IV

    Catalog No: CFN90389
    CAS No: 89590-95-4
    Price: $100/20mg
    11-Oxomogroside IV

    Catalog No: CFN91126
    CAS No: 2096516-32-2
    Price: $268/5mg
    Mogroside IVa

    Catalog No: CFN92188
    CAS No: 88901-41-1
    Price: $268/10mg
    11-Oxomogroside IVa

    Catalog No: CFN95607
    CAS No: 952481-54-8
    Price: $338/10mg
    Mogroside IVe

    Catalog No: CFN92189
    CAS No: 88915-64-4
    Price: $288/10mg
    Mogroside II-A1

    Catalog No: CFN92947
    CAS No: 88901-44-4
    Price: Inquiry(manager@chemfaces.com)
    11-Oxomogroside II A1

    Catalog No: CFN95606
    CAS No: 942612-74-0
    Price: $318/5mg
    Mogroside III-A1

    Catalog No: CFN92193
    CAS No: 88901-42-2
    Price: $318/10mg
    Mogroside III-A2

    Catalog No: CFN92946
    CAS No: 88901-43-3
    Price: $338/5mg
    Pharm Biol. 2014 Jun;52(6):729-34.
    Protective effects and mechanisms of mogroside V on LPS-induced acute lung injury in mice.[Pubmed: 24621273]
    Mogroside V, a compound isolated from Momordica grosvenori Swingle, which belongs to the Cucurbitaceae, is a traditional Chinese medicine reported to have anti-inflammatory potential in murine macrophages and a murine ear edema model. OBJECTIVE: To investigate the effects and mechanisms of action of this compound in a model of acute lung injury (ALI) induced by lipopolysaccharides (LPS).
    METHODS AND RESULTS:
    Female BALB/c mice were treated with commercial Mogroside V (2.5, 5 and 10 mg/kg) for 1 h prior to intranasal injection of LPS (10 μg in 50 μl). After 12 h, airway inflammation in the ALI model was determined by the wet/dry weight (W/D) ratio, myeloperoxidase (MPO) activity of lung tissue, leukocyte recruitment and cytokine levels in the bronchoalveolar lavage fluid (BALF). Additionally, lung tissue was examined by histology and western blotting to investigate the changes in pathology and the signalling in the presence and absence of Mogroside V. Mogroside V at 5 and 10 mg/kg inhibited airway inflammation induced by LPS as measured by the decrease in the histological changes (44 and 67.3% reduction in lung injury score, respectively), a 28.9 and 55.3% reduction in lung MPO activity, and inflammatory cell counts, interleukin-1β (IL-1β, 382 and 280 pg/ml, respectively), IL-6 (378 and 232 pg/ml, respectively) and tumor necrosis factor-α (TNF-α, 12.5 and 7.8 ng/ml, respectively) levels in the BALF. Additionally, Mogroside V treatment reduced the activation of cyclooxygenase 2 (COX-2), inducible NO synthase (iNOS), and the nuclear factor (NF)-κB.
    CONCLUSIONS:
    Together, these data suggest that Mogroside V has the potential to protect against LPS-induced airway inflammation in a model of ALI.
    Rsc Adv., 2016, 6(9):7034-41.
    In vitro AMPK activating effect and in vivo pharmacokinetics of mogroside V, a cucurbitane-type triterpenoid from Siraitia grosvenorii fruits[Reference: WebLink]
    The aim of this study was to explore the anti-diabetic effects of cucurbitane-type triterpenoids, Mogroside V (MV) and its aglycone mogrol (MO), both isolated from the fruits of Siraitia grosvenorii Swingle, and to investigate the pharmacokinetic behaviors of MV and its metabolite MO in rats.
    METHODS AND RESULTS:
    The anti-diabetic effects by activating AMPK of MV and MO were evaluated in this study. Furthermore, a sensitive and specific liquid chromatography electrospray ionization-tandem mass spectrometry method for the simultaneous quantification of MV and its metabolite MO in rat plasma has been developed and validated. The assay has been successfully used for pharmacokinetic evaluation of MV and its metabolite MO after intravenous and oral administration of a single dose of MV in rats at 2.0 mg kg−1 and 5.0 mg kg−1, respectively. In vitro activities indicated that MV and its aglycone MO were both potent AMPK activators. MV and MO could activate the AMPK heterotrimer α2β1γ1 by 2.4 and 2.3 fold with an EC50 of 20.4 and 4.2 μM, respectively. This result suggested AMPK activation by MV and MO was proved to contribute at least partially to the anti-diabetic properties of S. grosvenorii. The pharmacokinetic results showed that MV was rapidly deglycosylated and metabolized into MO, and both of these were determined after intravenous administration of 2.0 mg kg−1 of MV in rats. MV was not detected in rat plasma after oral administration, whereas a trace amount of MO was found. The oral absolute bioavailability (F) of MV was estimated to be 8.73 ± 1.46% and the elimination half-life (t1/2) of metabolite MO in rats was 2.46 ± 0.19 h.
    CONCLUSIONS:
    It was indicated that MV showed poor absorption and/or strong metabolism in vivo. Its metabolite MO may be the main pharmacological activity form after oral administration of MV in rats.
    Phytochem Anal. 2013 Jul-Aug;24(4):381-5.
    Analysis of Mogroside V in Siraitia grosvenorii with micelle-mediated cloud-point extraction.[Pubmed: 23349010]
    Mogroside V is the main effective ingredient of Siraitia grosvenorii used as a natural sweet food as well as a traditional Chinese medicine. The sample pre-treatment prior to chromatographic analysis requires large amounts of toxic organic solvents and is time consuming. To develop an effective and simple method for extracting and determining Mogroside V of Siraitia grosvenorii.
    METHODS AND RESULTS:
    Mogroside V was extracted and preconcentrated by micelle-mediated cloud-point extraction with nonionic surfactant isotridecyl poly (ethylene glycol) ether (Genapol® X-080). The obtained solutions containing Mogroside V were analysed by high-performance liquid chromatography (HPLC) with ultraviolet (UV) detection. The chromatographic separation was performed on a C18 -column using gradient elution with acetonitrile and water at 203 nm. The cloud-point extraction yield was 80.7% while the pre-concentration factor was about 10.8. The limit of detection was 0.75 μg/mL and the limit of quantification was 2 μg/mL. The relative standard deviations for intra- and interday precisions of Mogroside V were less than 8.68% and 5.78%, respectively, and the recoveries were between 85.1% and 103.6%.
    CONCLUSIONS:
    The HPLC-UV method based on micelle-mediated cloud-point extraction for determination Mogroside V in Siraitia grosvenorii was environmentally friendly, simple and sensitive.
    Decursitin D

    Catalog No: CFN95002
    CAS No: 245446-61-1
    Price: $388/5mg
    Carasiphenol C

    Catalog No: CFN95045
    CAS No: 868168-04-1
    Price: $368/5mg
    Lonicerin

    Catalog No: CFN95055
    CAS No: 25694-72-8
    Price: $168/10mg
    Isorubrofusarin 10-gentiobioside

    Catalog No: CFN95119
    CAS No: 200127-93-1
    Price: $338/10mg
    Sphenanlignan

    Catalog No: CFN95245
    CAS No: 866347-36-6
    Price: $318/5mg
    11-Oxomogroside IIA2

    Catalog No: CFN95305
    CAS No: 2170761-37-0
    Price: $368/5mg
    8'-O-(3-hydroxy-3-methylglutaryl)-8'-hydroxyabscisic acid

    Catalog No: CFN95308
    CAS No: 69790-31-4
    Price: $318/5mg
    Planispine A

    Catalog No: CFN95348
    CAS No: 1202761-42-9
    Price: $318/10mg
    Methyl 2-hydroxy-3,4-dimethoxybenzoate

    Catalog No: CFN95383
    CAS No: 6395-23-9
    Price: $268/5mg
    12-Acetoxy ganoderic acid D

    Catalog No: CFN95535
    CAS No: N/A
    Price: $318/5mg